Simulations Plus, Inc.
NASDAQ:SLP
27.49 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Simulations Plus, Inc. |
Symbool | SLP |
Munteenheid | USD |
Prijs | 27.49 |
Beurswaarde | 551,647,328 |
Dividendpercentage | 0.49% |
52-weken bereik | 27.22 - 51.22 |
Industrie | Health Information Services |
Sector | Healthcare |
CEO | Mr. Walter S. Woltosz M.A.S., M.S. |
Website | https://www.simulations-plus.com |
An error occurred while fetching data.
Over Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)